Karyopharm has appointed Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer.

In this role, Macomber will be responsible for leading and directing the financial activities of the Company.

"Lori is an outstanding addition to the Karyopharm team. She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow XPOVIO revenue and maintain our disciplined expense management as we progress our clinical pipeline," said Richard Paulson, President and Chief Executive Officer of Karyopharm.

"I am thrilled to join Karyopharm at this important stage as we advance our pipeline of novel therapies and look forward to working with the leadership team and contributing to the company's success," said Macomber.

"I am impressed with both the team and the science and I am excited to be a part of bringing much needed therapies to patients," added Macomber.

Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals.

Most recently, she served as Chief Financial Officer at Legend Biotech Corporation, a publicly traded, commercial-stage biopharmaceutical company.  Previously, Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.

In connection with Macomber's appointment as Chief Financial Officer, effective as of January 31, 2025 (the Grant Date), the Company granted Macomber inducement awards consisting of (i) a non-statutory stock option to purchase 650,000 shares of Karyopharm's common stock (the Inducement Option) and (ii) 160,000 restricted stock units (the Inducement RSU Award).

These awards were granted pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to Ms. Macomber entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).